184 related articles for article (PubMed ID: 17477093)
1. [Fibrates and markers of inflammation].
Broncel M
Pol Merkur Lekarski; 2007 Jan; 22(127):58-61. PubMed ID: 17477093
[TBL] [Abstract][Full Text] [Related]
2. Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha activators: clinical and experimental evidence.
Zambon A; Gervois P; Pauletto P; Fruchart JC; Staels B
Arterioscler Thromb Vasc Biol; 2006 May; 26(5):977-86. PubMed ID: 16424352
[TBL] [Abstract][Full Text] [Related]
3. Therapeutical effects of PPAR agonists assessed by biomarker modulation.
Chinetti-Gbaguidi G; Fruchart JC; Staels B
Biomarkers; 2005 Nov; 10 Suppl 1():S30-6. PubMed ID: 16298909
[TBL] [Abstract][Full Text] [Related]
4. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease.
Staels B; Maes M; Zambon A
Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):542-53. PubMed ID: 18628776
[TBL] [Abstract][Full Text] [Related]
5. [Nonlipid effects of fibrates].
Celińska-Löwenhoff M; Undas A
Przegl Lek; 2004; 61(2):99-101. PubMed ID: 15230150
[TBL] [Abstract][Full Text] [Related]
6. Lipid-lowering therapy is related to inflammatory markers and 3-year mortality in patients with critical limb ischemia.
Isma N; Barani J; Mattiasson I; Lindblad B; Gottsäter A
Angiology; 2008; 59(5):542-8. PubMed ID: 18388063
[TBL] [Abstract][Full Text] [Related]
7. PPAR-alpha: therapeutic role in diabetes-related cardiovascular disease.
Cheng AY; Leiter LA
Diabetes Obes Metab; 2008 Sep; 10(9):691-8. PubMed ID: 17593234
[TBL] [Abstract][Full Text] [Related]
8. [Inflammatory markers and cytokines in cardiovascular disease].
Ogiwara F; Takahashi M; Ikeda U
Rinsho Byori; 2004 Aug; 52(8):686-92. PubMed ID: 15478624
[TBL] [Abstract][Full Text] [Related]
9. Arterial stiffness and inflammatory response to psychophysiological stress.
Ellins E; Halcox J; Donald A; Field B; Brydon L; Deanfield J; Steptoe A
Brain Behav Immun; 2008 Aug; 22(6):941-8. PubMed ID: 18316176
[TBL] [Abstract][Full Text] [Related]
10. [Influence of combined, hypolipemic therapy on lipids and non-lipid atherosclerosis risk factors].
Broncel M; Balcerak M; Chojnowska-Jezierska J
Pol Merkur Lekarski; 2007 Jan; 22(127):62-5. PubMed ID: 17477094
[TBL] [Abstract][Full Text] [Related]
11. Macrophage expression of peroxisome proliferator-activated receptor-alpha reduces atherosclerosis in low-density lipoprotein receptor-deficient mice.
Babaev VR; Ishiguro H; Ding L; Yancey PG; Dove DE; Kovacs WJ; Semenkovich CF; Fazio S; Linton MF
Circulation; 2007 Sep; 116(12):1404-12. PubMed ID: 17724261
[TBL] [Abstract][Full Text] [Related]
12. The potential use of PPARalpha agonists as immunosuppressive agents.
Cunard R
Curr Opin Investig Drugs; 2005 May; 6(5):467-72. PubMed ID: 15912959
[TBL] [Abstract][Full Text] [Related]
13. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA
Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582
[TBL] [Abstract][Full Text] [Related]
14. Effect of influenza vaccine on markers of inflammation and lipid profile.
Tsai MY; Hanson NQ; Straka RJ; Hoke TR; Ordovas JM; Peacock JM; Arends VL; Arnett DK
J Lab Clin Med; 2005 Jun; 145(6):323-7. PubMed ID: 15976761
[TBL] [Abstract][Full Text] [Related]
15. Anti-atherogenic properties of fibrates may be largely due to their anti-inflammatory effects.
Ye HJ; Zhao SP
Med Hypotheses; 2006; 66(3):495-500. PubMed ID: 16289368
[TBL] [Abstract][Full Text] [Related]
16. [Molecular mechanism of action of the fibrates].
Fruchart JC; Duriez P; Staels B
J Soc Biol; 1999; 193(1):67-75. PubMed ID: 10851558
[TBL] [Abstract][Full Text] [Related]
17. Effects of fenofibrate on inflammatory cytokines and blood pressure in patients with hypertriglyceridemia.
Ye P; Li JJ; Su G; Zhang C
Clin Chim Acta; 2005 Jun; 356(1-2):229-32. PubMed ID: 15936324
[No Abstract] [Full Text] [Related]
18. The treatment of dyslipidemia--what's left in the pipeline?
Rau O; Zettl H; Popescu L; Steinhilber D; Schubert-Zsilavecz M
ChemMedChem; 2008 Feb; 3(2):206-21. PubMed ID: 17963209
[TBL] [Abstract][Full Text] [Related]
19. The value of C-reactive protein as a marker of systemic inflammation in stable chronic obstructive pulmonary disease.
Karadag F; Kirdar S; Karul AB; Ceylan E
Eur J Intern Med; 2008 Mar; 19(2):104-8. PubMed ID: 18249305
[TBL] [Abstract][Full Text] [Related]
20. Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?
Barter PJ; Rye KA
Arterioscler Thromb Vasc Biol; 2008 Jan; 28(1):39-46. PubMed ID: 17717290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
